title: Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode.
abstract: Plasmids expressing different domains of the hepatis C virus (HCV) envelope E2 glycoprotein from a genotype 1a isolate were constructed to compare the immunogenic potential of E2 in nucleic acid-based immunizations. One plasmid, pCIE2t, expressed a C-terminally truncated form of E2, while others, pS2.SE2A to pS2.SE2E, encoded the adjacent 60-amino-acid (aa) sequences of E2 (inserts A to E) expressed as a fusion with the hepatitis B virus surface antigen. BALB/c mice were given injections of the plasmids intramuscularly (i.m.) or intraepidermally (i.e.) via a gene gun (biolistic introduction), and induced humoral immune responses were evaluated. The i.e. injections resulted in higher seroconversion rates and antibody titers, up to 100-fold, than did the i.m. injections (P = 0.01 to 0.04). Three restricted immunogenic domains, E2A (aa 384 to 443), E2C (aa 504 to 555), and E2E (aa 609 to 674), that yielded antibody titers ranging from 1:59 to > 1:43,700 could be identified. Subtype 1a- and 1b-derived E2 antigens and synthetic peptides were used in Western blot and enzyme-linked immunosorbent assay analyses, which revealed that the cross-reactivity of the plasmid-induced antibodies was linked both to the type of antigen expressed and to the injection mode. Induced anti-E2 antibodies could immunoprecipitate noncovalent E1E2 complexes believed to exist on the surface of HCV virions. This study allowed us to identify restricted immunogenic domains within E2 and demonstrated that different routes of injection of HCV E2 plasmids can result in quantitatively and qualitatively different humoral immune responses.
authors.affiliation: INSERM U271, Lyon, France.
authors.forename: I
authors.initials: I
authors.lastname: Nakano
authors.forename: G
authors.initials: G
authors.lastname: Maertens
authors.forename: M E
authors.initials: ME
authors.lastname: Major
authors.forename: L
authors.initials: L
authors.lastname: Vitvitski
authors.forename: J
authors.initials: J
authors.lastname: Dubuisson
authors.forename: A
authors.initials: A
authors.lastname: Fournillier
authors.forename: G
authors.initials: G
authors.lastname: De Martynoff
authors.forename: C
authors.initials: C
authors.lastname: Trepo
authors.forename: G
authors.initials: G
authors.lastname: Inchauspe
mesh_terms: D000818:Animals; D019470:Biolistics; D018604:Epitope Mapping; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000276:immunology*; D018936:Hepatitis C Antigens / Q000235:genetics; D007114:Immunization; D007273:Injections, Intramuscular; D051379:Mice; D008807:Mice, Inbred BALB C; D010957:Plasmids; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000235:genetics*; D014761:Viral Hepatitis Vaccines / Q000276:immunology*
chemical_list: D018937:Hepatitis C Antibodies; D018936:Hepatitis C Antigens; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D014761:Viral Hepatitis Vaccines; C091015:glycoprotein E2, Hepatitis C virus